Pediatrix Medical Group, Inc. MD
Pediatrix is a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 37 states. During 2024, we formalized our practice portfolio management plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. As of December 31, 2024, these plans were completed. Additionally, we exited our primary and urgent care service line during 2024 based on a review of the cost and time that would be required to build the platform to scale. At December 31, 2025, our national network comprised approximately 2,295 affiliated physicians, including 1,350 physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units ("NICUs"), to babies born prematurely or with medical complications. We have over 475 affiliated physicians who provide maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including over 230 physicians providing pediatric intensive care, 220 physicians providing hospital-based pediatric care, and 20 physicians providing pediatric surgical care.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B | $1.73B | $1.78B | $1.72B | $3.25B | $3.18B |
| SG&A | $240.8M | $238.4M | $227.5M | $231.4M | $263.4M | $248.9M | $244.5M | $232.2M | $385.9M | $372.6M |
| Total operating expenses | $1.71B | $2.08B | $1.99B | $1.80B | $1.71B | $1.64B | $1.61B | $1.47B | $2.80B | $2.61B |
| Operating income | $208.8M | -$68.7M | $7.3M | $172.7M | $202.9M | $98.1M | $171.8M | $248.4M | $454.9M | $571.7M |
| Interest expense | $36.0M | $40.7M | $42.1M | $39.7M | $68.7M | $110.5M | $118.9M | $92.9M | $74.6M | $63.1M |
| Pre-tax income | $216.4M | -$101.3M | -$48.4M | $81.4M | $135.2M | $7.1M | $58.8M | $166.2M | $385.7M | $513.8M |
| Income tax | $51.0M | $2.3M | $12.0M | $18.8M | $27.2M | $16.7M | $16.6M | $44.7M | $80.2M | $189.2M |
| Net income | $165.4M | -$99.1M | -$60.4M | $66.3M | $131.0M | -$796.5M | -$1.50B | $268.6M | $320.4M | $324.9M |
| EPS, basic | 1.97 | -1.19 | -0.73 | 0.79 | 1.54 | -9.55 | -17.94 | 2.95 | 3.47 | 3.52 |
| EPS, diluted | 1.94 | -1.19 | -0.73 | 0.79 | 1.53 | -9.55 | -17.83 | 2.93 | 3.45 | 3.49 |
| Shares, diluted (wtd. avg.) | $85.3M | $83.3M | $82.2M | $84.1M | $85.8M | $83.4M | $84.0M | $91.6M | $93.0M | $93.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $375.2M | $229.9M | $73.3M | $9.8M | $387.4M | $1.12B | $107.9M | $40.8M | $40.4M | $55.7M |
| Short-term investments | $124.5M | $118.6M | $104.5M | $93.2M | $99.7M | $104.9M | $74.5M | $21.9M | — | — |
| Receivables | $229.7M | $260.0M | $272.3M | $296.8M | $301.8M | $241.9M | $434.3M | $506.7M | $504.0M | $495.3M |
| Total current assets | $763.5M | $639.6M | $483.5M | $428.0M | $840.6M | $1.55B | $731.5M | $660.0M | $627.2M | $587.1M |
| Property, plant and equipment | $39.2M | $39.2M | $75.6M | $73.3M | $70.2M | $76.2M | $72.7M | $90.4M | $123.5M | $103.1M |
| Goodwill | $1.26B | $1.24B | $1.38B | $1.53B | $1.51B | $1.48B | $1.48B | $4.06B | $4.28B | $3.85B |
| Other intangibles | $16.9M | $11.6M | $21.2M | $18.5M | $21.6M | $26.6M | $28.6M | $313.2M | $639.9M | $668.5M |
| Total assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B | $3.35B | $4.15B | $5.94B | $5.87B | $5.34B |
| Accounts payable | $37.2M | $46.4M | $34.6M | $31.9M | $36.6M | $59.8M | $35.4M | $31.1M | $34.6M | $28.5M |
| Short-term debt | — | — | — | — | — | — | — | — | — | $20.0M |
| Total current liabilities | $458.9M | $434.1M | $388.9M | $427.0M | $427.4M | $444.3M | $541.8M | $502.8M | $531.4M | $448.9M |
| Long-term debt | — | $611.2M | $622.2M | $637.2M | $989.7M | $1.70B | $1.70B | $1.97B | $1.85B | $1.68B |
| Total liabilities | $1.38B | $1.39B | $1.37B | $1.46B | $1.83B | $2.60B | $2.65B | $2.85B | $2.80B | $2.58B |
| Retained earnings | -$83.2M | -$248.5M | -$149.5M | -$89.1M | -$155.4M | -$286.4M | $510.1M | $2.09B | $2.05B | $1.79B |
| Total equity | $865.9M | $764.9M | $849.1M | $891.6M | $896.7M | $747.7M | $1.50B | $3.09B | $3.07B | $2.76B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $271.1M | $206.6M | $137.3M | $166.9M | $76.7M | $204.6M | $357.7M | $313.7M | $511.4M | $443.8M |
| Depreciation and amortisation | $21.8M | $32.2M | $36.2M | $35.6M | $32.1M | $28.4M | $25.9M | $24.4M | $78.9M | $89.3M |
| Stock-based compensation | $18.0M | $11.9M | $12.3M | $16.1M | $19.0M | $39.0M | $33.4M | $36.6M | $28.8M | $34.0M |
| Investing cash flow | -$18.3M | -$35.4M | -$48.2M | -$57.0M | -$53.1M | $815.5M | $102.5M | -$142.8M | -$576.6M | -$821.2M |
| Financing cash flow | -$107.5M | -$14.5M | -$25.7M | -$487.6M | -$760.1M | -$4.2M | -$393.1M | -$170.6M | $89.7M | $381.6M |
| Buybacks | $86.7M | $1.7M | $919.0K | $88.5M | $4.7M | $8.5M | $145.3M | $302.2M | $70.2M | $61.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-058074.
Others in SIC 8060
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| EHC | Encompass Health Corp | $12.01B | 22.0x | 10.5% |